1. Home
  2. AMBO vs GLTO Comparison

AMBO vs GLTO Comparison

Compare AMBO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ambow Education Holding Ltd.

AMBO

Ambow Education Holding Ltd.

HOLD

Current Price

$3.24

Market Cap

11.9M

Sector

Real Estate

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$21.13

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMBO
GLTO
Founded
2000
2011
Country
United States
Denmark
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.9M
54.5M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
AMBO
GLTO
Price
$3.24
$21.13
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
20.4K
103.2K
Earning Date
08-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.69
N/A
Revenue
$9,699,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.04
N/A
Revenue Growth
23.73
N/A
52 Week Low
$1.59
$2.01
52 Week High
$6.75
$38.33

Technical Indicators

Market Signals
Indicator
AMBO
GLTO
Relative Strength Index (RSI) 38.06 43.57
Support Level $2.69 $21.56
Resistance Level $3.30 $38.33
Average True Range (ATR) 0.43 3.98
MACD -0.04 -1.44
Stochastic Oscillator 28.52 2.37

Price Performance

Historical Comparison
AMBO
GLTO

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: